The purpose of this study is to find out what effects (good and/or bad) there are to adding
the new investigational drug TaK-700 (also called orteronel) to standard hormone therapy
which is used to treat prostate cancer as compared to the standard of hormone therapy
alone. The combination of TaK-700 and standard hormone therapy is considered
The subject will be [Quote]randomized[Quote] into one of the study groups described below.
Subjects in Group 1 (often called [Quote]arm 1[Quote]) will receive standard hormone therapy plus
TaK-700. Leuprolide acetate (Lupron) or goserelin acetate (Zoladex) will be given as a shot in
the muscle once every 3 months. The subject will take TaK-700 as a tablet twice every day.
if the subject has not received hormone therapy before and have pain from the cancer, the subject will
take TaK-700 for seven days before receiving leuprolide acetate (Lupron) or goserelin acetate
(Zoladex). if you have no pain, you may start TaK-700 on the same day as leuprolide acetate
(Lupron) or goserelin acetate (Zoladex).
Subjects in Group 2 (often called [Quote]arm 2[Quote]) will receive standard treatment with hormone
therapies. Leuprolide acetate (Lupron) or goserelin acetate (Zoladex) will be given as a shot in
the muscle once every 3 months. You will take bicalutamide (Casodex) as a tablet
once every day. This is standard hormone therapy will be giveneven if the subjects
were not in this research study. if the subject has received hormone therapy before and have
pain from the cancer, the subject will take bicalutamide (Casodex) for seven days before receiving
leuprolide acetate (Lupron) or goserelin acetate (Zoladex). if the subject has no pain, the subject may start
bicalutamide (Casodex) on the same day as leuprolide acetate (Lupron) or goserelin acetate
There are two patient populations eligible for the study: those who have not started any therapy
with LHRH agonist or antagonist (Early Induction Group) and those who have already started
therapy with LHRH agonist or antagonist within the 30 days prior to registration (Late Induction
Group). Subjects must be registered within 30 days of first injection of the LHRH agonist or
Disease Related Criteria:
- All patients must have a histologically or cytologically proven diagnosis of
adenocarcinoma of the prostate. All patients must have distant metastatic
disease as evidenced by soft tissue and/or bony metastases prior to initiation of
androgen deprivation therapy.
- Patients who have measurable disease must have radiographic assessment
(abdominal/pelvic CT or MRI) within 28 days of the first injection of LHRH agonist.
Non-measurable disease must also be assessed (e.g., bone scan) in all patients
within 42 days of the first injection of LHRH agonist. All disease must be
assessed and documented on the Baseline Tumor Assessment Form.
Prior Therapy Criteria:
- Patients may have received prior neoadjuvant and/or adjuvant hormonal therapy,
but it must not have lasted for more than 36 months. Single or combination
therapy allowed. At least 6 months must have elapsed since completion of
androgen deprivation therapy in the neoadjuvant and/or adjuvant setting, and
serum testosterone must be within institutional limits of normal at the time of
- Patients may have received palliative radiotherapy for symptomatic bone or
visceral metastasis prior to registration. Radiotherapy must have been completed
at least 14 days prior to registration and patient must have recovered from all side
- Patients may have received prior surgery. For all major surgeries, at least 14
days must have elapsed since completion and patient must have recovered from
all major side effects of surgery per investigator[Single Quote]s assessment.
- Patients may have received or plan to receive concurrent bone targeting agents
that do not have an effect on PSA (e.g. denosumab or bisphosphonate).
- Patients with no plans to receive any other experimental therapy while on
the protocol treatment. Previous experimental therapy must have been
completed within 28 days prior to registration.
- Patients who have had no more than 30 days of prior medical castration for
metastatic prostate cancer prior to registration. The start date of medical
castration is considered the day the patient first received an injection of a LHRH
agonist, not an oral antiandrogen.
- Patients must have a PSA >= 2 ng/mL obtained within 90 days prior to initiation of
androgen deprivation therapy for early induction or prior to registration for late
- A DEXA scan must be obtained within 2 years prior to registration.
- Patients must have a left ventricular ejection fraction (LVEF) within institutional
normal limits by echocardiogram within 42 days prior to registration.
- Patients must have adequate hepatic function as evidenced by bilirubin <= 2 x
institutional upper limit of normal (ULN), SGOT (AST) and SGPT (ALT) <= 3 x
institutional ULN, or <= 5 x institutional ULN if liver metastases are present. These
results must be obtained within 28 days prior to registration.
- Patients must have adequate renal function as evidenced by calculated creatinine
clearance >= 40 mL/min using a serum creatinine obtained within 28 days prior to
- Patients must have adequate hematologic function as evidenced by leukocytes >=
3,000/mcL, absolute neutrophil count (ANC) >= 1,500/mcL, hemoglobin >= 9 g/dL,
and platelets >= 100,000/mcL. These results must be obtained within 28 days
prior to registration.
- Patients must have a Zubrod performance status of 0 - 2. Zubrod performance status 3 will be allowed if from bone pain only.
- Patients must be >= 18 years of age.
- Men of reproduction potential and those who are surgically sterilized (i.e., postvasectomy)
must agree to practice effective barrier contraception or agree to
abstain from intercourse while receiving treatment on this study and for at least 4
months after protocol treatment ends.
- Patients must be offered the opportunity to participate in speciman banking for
future use to include translational medicine studies.
- Patients or their legally authorized representative must be informed of the
investigational nature of this study and must sign and give written informed
consent in accordance with institutional and federal guidelines. Voluntary written informed consent must be obtained before performance of any
study-related procedure not part of normal medical care, with the understanding
that consent may be withdrawn by the patient at any time without prejudice to
future medical care.